DXB.ASX: Half-Year Financial Report & Appendix 4D - 31 December 2024

Half-Year Financial Report & Appendix 4D - 31 December 2024

Stock	Dimerix Ltd (DXB.ASX)
Release Time	25 Feb 2025, 9:07 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Dimerix Reports H1 2024 Financial Results

Key Points

$21.1 million cash reserve
$11.4 million R&D expenditure
$458 million upfront & potential milestone licensing fees for DMX-200

Full Summary

Dimerix Limited reported its half-year financial results for the period ended 31 December 2024. The company reported a $21.1 million cash reserve, $11.4 million in R&D expenditure, and $1.4 million in operating costs. Dimerix also announced $458 million in upfront and potential milestone licensing fees for its DMX-200 drug candidate across three regional partnering agreements. During the period, Dimerix continued to focus on the development of its DMX-200 drug candidate for the treatment of Focal Segmental Glomerulosclerosis (FSGS), with the FSGS ACTION3 Phase 3 study progressing and the company signing a third licensing partner in Japan. The company's goal is to develop patient-friendly products that treat unmet medical needs, and it is committed to integrating Environmental, Social, and Governance (ESG) considerations across its operations.

Guidance

Dimerix reported a $21.1 million cash reserve as of 31 December 2024 and $458 million in upfront and potential milestone licensing fees for its DMX-200 drug candidate across three regional partnering agreements.